The effect of TCAs on CYP2D6 activity in vivo

被引：0
|
作者：
Szewczuk-Boguslawska, M. [1 ]
Kiejna, A. [1 ]
Beszlej, J. [1 ]
Orzechowska-Juzwenko, K. [1 ]
机构：
[1] Univ Med, Wroclaw, Poland
来源：
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY | 2006年 / 9卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S251 / S251
页数：1
相关论文
共 50 条
  • [21] Is CYP2D6 phenotype predictable from CYP2D6 genotype?
    Kiss, Adam Ferenc
    Toth, Katalin
    Juhasz, Cintia
    Temesvari, Manna
    Paulik, Jozsef
    Hirka, Gabor
    Monostory, Katalin
    MICROCHEMICAL JOURNAL, 2018, 136 : 209 - 214
  • [22] The effect of CYP 2D6 genotype and CYP2D6 inhibitors on tamoxifen
    Stearns, V
    Hayes, DF
    Jin, Y
    Ullmer, L
    Nguyen, A
    Storniolo, AM
    Flockhart, U
    Desta, Z
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 5S - 5S
  • [23] Serum flecainide S/R ratio reflects the CYP2D6 genotype and changes in CYP2D6 activity
    Doki, Kosuke
    Sekiguchi, Yukio
    Kuga, Keisuke
    Aonuma, Kazutaka
    Homma, Masato
    DRUG METABOLISM AND PHARMACOKINETICS, 2015, 30 (04) : 257 - 262
  • [24] CYP2D6 expression is regulated by polymorphisms that affect splicing and trancription: new biomarkers for CYP2D6 activity
    Wang, Danxin
    Poi, Ming J.
    Sun, Xiaochun
    Gaedigk, Andrea
    Leeder, J. Steven
    Sadee, Wolfgang
    FASEB JOURNAL, 2013, 27
  • [25] Impact of CYP2D6*2, CYP2D6*35, rs5758550, and related haplotypes on risperidone clearance in vivo
    Storset, Elisabet
    Braten, Line Skute
    Ingelman-Sundberg, Magnus
    Johansson, Inger
    Molden, Espen
    Kringen, Marianne Kristiansen
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 80 (10) : 1531 - 1541
  • [26] Common mutant alleles of CYP2D6 causing the defect of CYP2D6 enzyme activity in a Japanese population
    Ishiguro, A
    Kubota, T
    Sasaki, H
    Yamada, Y
    Iga, T
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 55 (04) : 414 - U3
  • [27] A novel CYP2D6 scoring system for the prediction of CYP2D6 activity: Application to tamoxifen metabolism.
    Borges, S.
    Li, L.
    Robarge, J.
    Nguyen, A.
    Azzouz, F.
    Desta, Z.
    Skaar, T.
    Flockhart, D. A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 : S67 - S67
  • [28] THE 'ENHANCER' SNP DOES NOT EXPLAIN VARIABILITY OF CYP2D6 ACTIVITY IN VIVO.
    Boone, E. C.
    Staggs, V. T.
    Pearce, R. E.
    Lata, R. F.
    Gaedigk, R.
    Jaime, L. K. Montane
    Cherner, M.
    Berard, A.
    Fridley, B. L.
    Dinh, J. C.
    Miller, N. A.
    Leeder, J.
    Gaedigk, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 : S57 - S57
  • [29] Variability of the dietary-derived CYP2D6 activity marker solanidine in vivo
    Mueller, J. P.
    Saromba, J.
    Ziegler, P.
    Tremmef', R.
    Rengelshausen, J.
    Schaeffeler, E.
    Just, K. S.
    Schwab, M.
    Kraus, T.
    Sting, J. C.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2024, 397 : S72 - S72
  • [30] Inter-individual Variability of In Vivo CYP2D6 Activity in Different Genotypes
    Chiba, Koji
    Kato, Motohiro
    Ito, Takashi
    Suwa, Toshio
    Sugiyama, Yuichi
    DRUG METABOLISM AND PHARMACOKINETICS, 2012, 27 (04) : 405 - 413
12345